CINECA IRIS Institutional Research Information System

NICOLINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.068
AS - Asia 7.539
EU - Europa 4.413
SA - Sud America 836
AF - Africa 237
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 27.107
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.601
SG - Singapore 2.380
CN - Cina 2.314
IT - Italia 1.253
HK - Hong Kong 1.219
BR - Brasile 741
SE - Svezia 636
BG - Bulgaria 564
VN - Vietnam 495
CA - Canada 405
UA - Ucraina 377
TR - Turchia 364
DE - Germania 345
KR - Corea 318
FI - Finlandia 290
FR - Francia 234
RU - Federazione Russa 227
GB - Regno Unito 213
JP - Giappone 157
CH - Svizzera 151
CI - Costa d'Avorio 117
IN - India 78
BD - Bangladesh 41
IQ - Iraq 34
MX - Messico 29
AR - Argentina 28
SN - Senegal 23
SA - Arabia Saudita 22
UZ - Uzbekistan 19
BE - Belgio 18
ZA - Sudafrica 18
BJ - Benin 17
PK - Pakistan 17
NL - Olanda 14
AT - Austria 13
CO - Colombia 13
EC - Ecuador 13
ID - Indonesia 13
CZ - Repubblica Ceca 12
MA - Marocco 12
PY - Paraguay 12
VE - Venezuela 12
ES - Italia 10
GR - Grecia 10
PL - Polonia 10
TN - Tunisia 10
AU - Australia 9
JO - Giordania 9
JM - Giamaica 8
KE - Kenya 7
EG - Egitto 6
ET - Etiopia 6
LT - Lituania 6
MY - Malesia 6
PH - Filippine 6
RO - Romania 6
CL - Cile 5
HU - Ungheria 5
IE - Irlanda 5
IR - Iran 5
NP - Nepal 5
PE - Perù 5
BB - Barbados 4
DK - Danimarca 4
IL - Israele 4
LB - Libano 4
OM - Oman 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
BS - Bahamas 3
DZ - Algeria 3
KZ - Kazakistan 3
MU - Mauritius 3
PA - Panama 3
TH - Thailandia 3
TW - Taiwan 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
DO - Repubblica Dominicana 2
EU - Europa 2
HN - Honduras 2
KG - Kirghizistan 2
LY - Libia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
Totale 27.088
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.423
Singapore 1.366
Ashburn 1.355
Ann Arbor 1.238
Hong Kong 1.212
Chandler 967
Fairfield 918
Houston 886
San Jose 697
Sofia 563
Dallas 545
Jacksonville 486
Milan 478
Shanghai 471
Beijing 432
Santa Clara 416
Seattle 377
Hefei 374
Ottawa 367
Wilmington 354
New York 343
Cambridge 336
Seoul 316
Nanjing 260
Izmir 258
Boardman 241
Princeton 229
Lawrence 220
Medford 214
Lauterbourg 185
Des Moines 167
Tokyo 150
Bern 139
Los Angeles 127
Abidjan 117
Ho Chi Minh City 112
Dearborn 101
Istanbul 93
Nanchang 89
Council Bluffs 86
Hanoi 86
Buffalo 80
Jüchen 75
Redondo Beach 73
Dong Ket 71
Florence 66
Serra 57
São Paulo 57
Kunming 56
Helsinki 54
San Diego 45
Shenyang 44
Chicago 37
Rome 37
Munich 35
Hebei 34
Ogden 34
The Dalles 34
Boulder 33
Columbus 33
Tianjin 33
Frankfurt am Main 32
Falls Church 28
Changsha 27
Rio de Janeiro 26
Dakar 23
Hangzhou 23
Redwood City 23
London 22
Pune 22
Guangzhou 21
Lancaster 20
Pisa 20
Jiaxing 19
Brussels 18
Da Nang 18
Norwalk 18
Orem 18
Cotonou 17
Düsseldorf 17
Orange 17
Phoenix 17
Auburn Hills 16
Brasília 14
Fuzhou 13
Lanzhou 13
Tashkent 13
Turku 13
Vienna 13
Washington 13
Curitiba 12
Jinan 12
Porto Alegre 12
Brooklyn 11
Genoa 11
Haiphong 11
Salvador 11
Belo Horizonte 10
Changchun 10
Dhaka 10
Totale 20.446
Salva come PNG Salva come JPEG
Nome #
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 227
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 223
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. 220
T cell-mediated immunity, eosinophils, sIL-2R, neopterin and interleukins 4, 6, 10, 12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 211
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study 208
Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs 205
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 196
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 193
Molecular markers in breast cancer: no longer a “free” run from laboratory to the clinic 190
Accuracy of an individual reference limit (IRL) during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel 188
Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease 188
Early diagnosis and treatment of breast cancer relapses 184
A rationale non-invasive schedule with tumor markers and instrumental exsaminations for “early” detection of bone metastases in breast cancer 184
Additional 5-FU-LV significantly increases survival in gastrointestinal cancer 182
Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment. 175
Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective six year study 174
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 174
A meta-analysis of the performance of serum tumour markers levels for early signalling distant metastases during post-operative follow-up of disease-free breast cancer patients 167
Stem cells: their role in breast cancer development and resistance to treatment. 166
Defining the critical hurdles in cancer immunotherapy. 165
Bone scintigraphy and tumor markers in the post-operative follow-up of breast, colorectal, prostate and renal cancer 165
CEA, TPA, GICA, CA 72-4 and CA 195 and their associations in the post-operative follow-up of colorectal cancer 162
Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 162
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin (PHA) and NK cytotoxic activity of peripheral blood lymphocytes in patients (pts) mastectomized for breast cancer 160
Tumor markers increase the diagnostic accuracy of skeletal metastases in breast cancer patients 159
Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. 159
Pilot study with subcutaneous (s.c.) low dose rIL-2 cyclically given in addition to 5-FU and leucovorin (LV) in metastatic colorectal cancer 158
Criteria to use serum tumour marker levels for early signalling distant metastases durino post-operative follow-up of disease-free breast cancer patients: laboratori and clinical aspects. 156
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 155
Lymphopressotherapy in chronic postmastectomy lymphedema 154
Postoperative monitoring of breast cancer patients with tumor markers 154
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin and NK cytotoxic activity of peripheral blood lymphocytes in patients mastectomized for breast cancer 154
Cell mediated immunity in disease free breast cancer patients 154
Cell mediated immunity (CMI) in breast cancer patients at the relapse 153
Tumoral markers in the kidney cancer: preliminary results 153
A rational non invasive schedule with tumor markers, bone scanning (BS) and "aimed" computed tomography (CT) or skeletal x - ray for "early" detection of bone metastases in breast cancer 153
Comparison of Ca 549 and TPS usefulness with CEA, TPA and Ca 15.3 in the post-operative follow-up of breast cancer patients 152
Impact on survival of "early" detection of colorectal cancer relapses with tumor markers 152
Circulating tumor cells (CTCs) in breast cancer post-operative follow-up: a preliminary comparison with serum CEA-TPA-CA15.3 tumor marker (TM) panel based monitoring. 152
Cyclic beta-interferon-interleukin-2 sequence in addition to antiestrogens significantly prolongs survival of endocrine dependent metastatic breast cancer patients 151
Microcirculation in chronic post-mastectomy lymphoedem 150
Urinary markers of bone resorption in breast cancer patients 150
Cell mediated immunity (CMI) in non relapsed breast cancer patients 149
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patints with breast cancer and benigne pathology 148
A rationale follow-up with CEA-TPA-CA15.3 tumor marker panel strongly decreases the conventional instrumental examinations to monitor metastatic breast cancer patients 148
T-cell mediated immunity (CMI) and B lymphocytes in breast cancer patients after mastectomy 146
Osteoporosis and biomaterial osteointegration 146
RELATIONSHIP AMONG CIRCULATING LEVELS OF THYROID HORMONES TSH AND TBG AFTER THYROIDECTOMY 145
Evaluation of CEA, TPA, Ca 15.3, Ca 549 and TPS in the monitoring of metastatic breast cancer 145
Atherosclerosis and cancer: common pathways on the vascular endothelium 145
Prognostic indices of overall survival (OS) and response to TAM and MAP in metastatic breast cancer patients 144
CEA, TPA, GICA, CA 72-4 and CA 195 in the post-operative follow-up of colorectal cancer 144
Large needle aspiration biopsy (LNAB) of palpable thyroid nodules refines the two FNA cytological diagnoses of microfollicular nodule and suspected cancer 144
Low s.c. rIL-2 doses cyclically given in advanced renal cancer patients 143
Large needle aspiration biopsy histology for the preoperative selection of the palpable thyroid nodule diagnosed by FNA cytology as microfollicular nodule, microfollicular nodule with atypical cells or suspected cancer 143
Usefulness of serum NSE and S-100 protein in patients with malignant melanoma: preliminary data 142
Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor biology 141
Bioabsorbable scaffold for in situ bone regeneration. 141
Uselfulness of serum CEA, GICA and ferritin measurement in the postoperative follow-up of renal cancer 140
In colorectal cancer a multistep therapy with subcutaneous (s.c.) low dose recombinant interleukin-2(rIL-2),5-fluorouracil (5-FU) and leucovorin(LV) prolongs the duration of responce and overall survival of patients with inoperable metastases 139
Subcutaneous (s.c.) low dose rIL-2 cyclically given increases the response rate (RR) and prolongs the response to 5-FU and LV of metastatic colorectal cancer patients (pts): an update of results 139
From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules 139
Our experience with subcutaneous (s.c.) rIL2 therapy in advanced cancer patients 138
Preoperative histological diagnosis of palpable thyroid nodules: accuracy of aspiration needle biopsy 138
TSH levels are affected by time of blood sampling in the follow up of levothyroxine substitution therapy: preliminary report 138
Emergent biomolecular markers for improving preoperative diagnosis of thyroid tumors 138
Role of obesity , alcohol and smoking on bone health 137
TSH levels are affected by time of blood sampling in untreated euthyroid goitrous patients. 136
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients 136
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 135
Subcutaneous (sc) low dose rIL-2 cyclically given prolongs the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 134
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial 134
Advanced breast cancer: an update and controversies on diagnosis and therapy 134
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 133
Comparison Between Two Different Dynamic Methods for Evaluating CEA-TPA-CA15.3 Tumor Marker ™ Panel Specificity in the Post-Operative Follow-up of Disease-Free Breast Cancer Patients: Preliminary Results 133
Home therapy with low-dose s.c. rIL-2 cycles to prolong the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 132
In colorectal cancer a multistep therapy with subcutaneous (s. c.) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) prolongs the duration of response and overall survival of patients with inoperable metastases 132
Serum levels of T-lymphocyte subpopulations, eosinophils, sIL-2R, neopterin and IL-4, IL-6, IL-10, IL-12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 132
Comparison between two groups of breast cancer patients submitted or not to a rational post-operative follow-up with tumor markers 131
Early detection of colorectal cancer relapses with tumor markers 131
intensive post operative follow of breast cancer patients with tumors markers: accuracy of serum MCA,Ca 15,3 and CEA, TPA,CA15.3 tumor maker panel for early detection of relapse. 131
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 131
Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies 130
Usefulness of a rationale post-operative follow-up of breast cancer with tumor markers 129
Prognostc value of tissue vascular endothelial growth factor in primary breast cancer 129
An intensive and risk-adapted follow-up with CEA-TPA-CA19.9-CA72.4 tumour marker panel and abdominal US in diagnosing operable recurrences from colorectal cancer: impact on survival. 128
Specificity of in individual reference limit (ISL) compared with conventional cut-off during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel. 128
Cytokines in the management of high risk or advanced breast cancer: an update and expectation 128
Cyclin D-1 prognostic value compared to axillary node status (N), ER, PgR, MIB-1 and p53 in breast cancer patients 2, 5 and more than 10 years after mastectomy. 127
Prognostic value of tissue vascular endothelial growth factor (VEGF) in primary breast cance 127
First Line Salvage Hormone Immunotherapy in Endocrine-Dependent Metastatic Breast Cancer 127
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. 127
Standardized use of serum tumor markers (TMs) for post-operative breast cancer follow-up: an impossible task? 127
Usefulness of “early” detection of colorectal cancer relapses with tumor markers 126
Metastatic colo rectal cancer : a pilot study with multistep therapy. 126
Therapy following “early” detection of relapse with the CEA-TPA-CA15.3 panel after mastectomy prolongs overall survival 125
Aspiration needle biopsy refines preoperative diagnosis of thyroid nodules defined at fine needle aspiration as microfollicular nodule 125
Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis 125
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET 124
Methodological and clinical progress in thyroid tumor markers 123
Totale 15.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.942 3 157 15 79 406 312 23 79 124 37 52 655
2022/20232.324 323 178 132 220 295 372 18 188 424 9 140 25
2023/20241.995 351 251 253 114 273 346 23 52 39 21 36 236
2024/20255.532 31 236 44 349 327 407 559 364 648 836 657 1.074
2025/20265.576 302 878 704 289 442 665 958 250 324 483 177 104
2026/202736 36 0 0 0 0 0 0 0 0 0 0 0
Totale 27.219